WO2013004190A1 - 胺基丙二醇类衍生物、其制备方法和其药物组合物与用途 - Google Patents

胺基丙二醇类衍生物、其制备方法和其药物组合物与用途 Download PDF

Info

Publication number
WO2013004190A1
WO2013004190A1 PCT/CN2012/078244 CN2012078244W WO2013004190A1 WO 2013004190 A1 WO2013004190 A1 WO 2013004190A1 CN 2012078244 W CN2012078244 W CN 2012078244W WO 2013004190 A1 WO2013004190 A1 WO 2013004190A1
Authority
WO
WIPO (PCT)
Prior art keywords
tert
group
hydrogen
butyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2012/078244
Other languages
English (en)
French (fr)
Chinese (zh)
Inventor
韩伟娟
张海婧
汪小涧
金晶
李刚
张翼
肖琼
周婉琪
陈晓光
尹大力
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Materia Medica of CAMS and PUMC
Original Assignee
Institute of Materia Medica of CAMS and PUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Materia Medica of CAMS and PUMC filed Critical Institute of Materia Medica of CAMS and PUMC
Priority to EA201490221A priority Critical patent/EA201490221A1/ru
Priority to JP2014517431A priority patent/JP2014523887A/ja
Priority to CN201280032727.7A priority patent/CN103702973B/zh
Priority to KR1020147003101A priority patent/KR20140048239A/ko
Priority to EP12808109.8A priority patent/EP2786982A4/en
Priority to US14/130,861 priority patent/US20140323501A1/en
Publication of WO2013004190A1 publication Critical patent/WO2013004190A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
    • C07C217/72—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Definitions

  • One aspect of the present invention provides an immunomodulatory agent which is excellent in therapeutic effect and low in toxicity, such as a compound of the formula (I) and a stereoisomer thereof.
  • R 61 , R 62 , R 63 , R 64 , R 65 and R 66 are independently selected from the group consisting of hydrogen, hydroxy, thiol, amino, aldehyde, carbocarbamoyl, halogen, nitro, cyano, C1-4 alkyl , C1-4 alkoxy, C1-4 alkylthio, C1-4
  • the alkylamino group includes a monoalkylamino group and a bisalkylamino group, a C1-4 alkoxy C1-4 alkyl group, an acyl group of C1-4, a C1-4 acyloxy group, a C1-4 amide group, a C1-4 halogenated alkyl group or a C2- 4 olefins.
  • the compound of the present invention or a pharmaceutical composition containing the same may be administered in a unit dosage form, which may be enterally or parenterally, such as oral, intravenous, intramuscular, subcutaneous, nasal, oral mucosa, eye, lung, and Respiratory tract, skin, vagina, rectum, etc.
  • 2-Bromopyrimidine (159 mg, 1.0 mmol) was dissolved in 10 mL of ethylene glycol dimethyl ether, followed by 4-phenoxyphenylboronic acid (257 mg, 1.2 mmol), water (2 mL), K 2 C0 3 ( 27 mg, 0.2 mmol), Pd(PPh 3 ) 4 (23 mg, 0.02 mmol), heated under reflux for 18 h under argon, quenched and cooled to room temperature.
  • the sodium solution was washed, dried over anhydrous sodium sulfate, filtered, and evaporated.
  • Crude petroleum ether: ethyl acetate 10: 1 over silica gel to give a pale yellow transparent oil 150 mg.
  • the starting material 2-C4-phenoxy-phenyl)-pyrimidine (800 mg, 3.226 mmol) was dissolved in 30 mL of anhydrous dichloromethane and bromoacetyl bromide (651 mg, 3.226 mmol) was added at 0 ° C
  • Anhydrous aluminum trichloride was added in batches, and the mixture was stirred at this temperature for 3 hours to stop stirring.
  • the reaction night was poured into a 2N hydrochloric acid ice water mixture and stirred for 30 min.
  • the liquid phase was separated and the aqueous phase was extracted with dichloromethane (30 mL).
  • the organic phase was washed successively with water and saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered and evaporated to give a pale yellow solid.
  • the starting material is 2-acetamido-2-[2-(4-(4-(2-n-propyloxazolyl)phenoxy)phenyl)ethyl]-1 , 3-propanedioic acid with stirring at room temperature Diethyl ester (1.0 g, 1.9 mmol) was dissolved in 14 mL of 95% ethanol, and K 2 HP0 4 (3.5 g, 15.1 mmol) was dissolved in 3.5 mL of distilled water and added to the reaction solution, followed by NaBH 4 (0.37 g).
  • the starting material is 2-acetamido-2-[2-(4-(4-(2-ethyloxazolyl)phenylthio)phenyl)-2-oxo-ethyl]-1, 3 under stirring at room temperature Diethyl malonate (0.46 g, 0.86 mmol) was dissolved in 6 mL of 95% ethanol.
  • the organic solvent diphenyl sulfide C20 g, 107.5 mmol) was dissolved in 200 mL of dry CH 2 C1 2 , added with chloroacetyl chloride (12.2 g, 107.5 mmol), and then slowly added in portions.
  • A1C1 3 (15.0 g, 112.4 mmol), after all the addition of A1C1 3 , naturally rise to room temperature and continue to stir for 4 h. The raw materials disappeared on the spot plate, and the reaction solution was poured into ice water and hydrochloric acid to decompose, and the organic layer was separated.
  • the ester (0.7 g, 1.4 mmol) was dissolved in 10 mL of 95% ethanol, and K 2 HP0 4 (2.5 g, 10.8 mmol) was dissolved in 2.5 mL of distilled water and added to the reaction solution, followed by NaBH 4 (0.27 g, 7.1).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/CN2012/078244 2011-07-06 2012-07-05 胺基丙二醇类衍生物、其制备方法和其药物组合物与用途 Ceased WO2013004190A1 (zh)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EA201490221A EA201490221A1 (ru) 2011-07-06 2012-07-05 Производные аминопропандиола, получение и фармацевтические композиции и применение
JP2014517431A JP2014523887A (ja) 2011-07-06 2012-07-05 アミノプロパンジオール誘導体、準備、および医薬品組成物および用途
CN201280032727.7A CN103702973B (zh) 2011-07-06 2012-07-05 胺基丙二醇类衍生物、其制备方法和其药物组合物与用途
KR1020147003101A KR20140048239A (ko) 2011-07-06 2012-07-05 아미노 프로판디올 유도체, 제조방법 및 약제학적 조성물 및 사용
EP12808109.8A EP2786982A4 (en) 2011-07-06 2012-07-05 AMINO-PROPYLENE GLYCOL DERIVATIVES, METHOD OF MANUFACTURING THEREOF, PHARMACEUTICAL COMPOSITION THEREFOR AND USE THEREOF
US14/130,861 US20140323501A1 (en) 2011-07-06 2012-07-05 Amino-propylene-glycol derivatives, preparation method and pharmaceutical composition and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201110188255.1 2011-07-06
CN2011101882551A CN102863345A (zh) 2011-07-06 2011-07-06 胺基丙二醇类衍生物、其制备方法和其药物组合物与用途

Publications (1)

Publication Number Publication Date
WO2013004190A1 true WO2013004190A1 (zh) 2013-01-10

Family

ID=47436521

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2012/078244 Ceased WO2013004190A1 (zh) 2011-07-06 2012-07-05 胺基丙二醇类衍生物、其制备方法和其药物组合物与用途

Country Status (7)

Country Link
US (1) US20140323501A1 (enExample)
EP (1) EP2786982A4 (enExample)
JP (1) JP2014523887A (enExample)
KR (1) KR20140048239A (enExample)
CN (2) CN102863345A (enExample)
EA (1) EA201490221A1 (enExample)
WO (1) WO2013004190A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014175287A1 (ja) 2013-04-26 2014-10-30 国立大学法人 京都大学 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物
CN111087359A (zh) * 2018-10-24 2020-05-01 中国医学科学院药物研究所 艾托莫德的制备方法
CN111087358A (zh) * 2018-10-24 2020-05-01 中国医学科学院药物研究所 普赛莫德的制备方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104844533B (zh) * 2014-02-17 2019-04-09 中国医学科学院药物研究所 含五元芳杂环的氨基丙二醇类化合物、其制备方法及其医药用途
IL315313A (en) * 2018-08-24 2024-10-01 Xeniopro GmbH Aromatic molecules for use in the treatment of pathological conditions
JP2021534214A (ja) * 2018-08-24 2021-12-09 ゼニオプロ ゲーエムベーハー 抗増殖活性を有するフェノキシ（ヘテロ）アリールエーテル
CN111087356B (zh) * 2018-10-24 2022-06-21 中国医学科学院药物研究所 一种艾托莫德的制备方法
CN115974803B (zh) * 2022-12-12 2024-04-09 渐宽(苏州)生物科技有限公司 一种普赛莫德的晶型及其制备方法和用途
CN116217507B (zh) * 2022-12-22 2024-12-20 渐宽(苏州)生物科技有限公司 一种艾托莫德的晶型及其制备方法和应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014525A2 (en) * 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Bi-aryl compound having immunosuppressive activity
WO2005044780A1 (ja) * 2003-11-10 2005-05-19 Kyorin Pharmaceutical Co., Ltd. アミノカルボン酸誘導体とその付加塩及びｓ１ｐ受容体調節剤
US6963012B2 (en) * 2001-09-27 2005-11-08 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
WO2006041015A1 (ja) * 2004-10-12 2006-04-20 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体とその付加塩及び免疫抑制剤
JP2007001921A (ja) * 2005-06-23 2007-01-11 Kyorin Pharmaceut Co Ltd アミノスルホン酸誘導体とその付加塩及びｓ１ｐ受容体調節剤
CN100351244C (zh) * 2002-05-27 2007-11-28 诺瓦提斯公司 双芳族链烷醇
WO2010042998A1 (en) * 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP796798A0 (en) * 1998-12-30 1999-01-28 Fujisawa Pharmaceutical Co., Ltd. New compound
PT1431284E (pt) * 2001-09-27 2008-01-21 Kyorin Seiyaku Kk Derivado de sulfureto de diarilo, um seu sal de adição e imunossupressor
EP1548003A4 (en) * 2002-09-19 2006-06-07 Kyorin Seiyaku Kk AMINO ALCOHOL DERIVATIVE, ADDITIONAL SALT AND IMMUNOSUPPRESIVE AGENT
US7989480B2 (en) * 2006-08-04 2011-08-02 Decode Genetics Ehf Aryl amino acid derivatives as inhibitors for treating inflammation
CN101501049B (zh) * 2006-08-08 2013-04-24 杏林制药株式会社 氨基磷酸酯衍生物以及将它们作为有效成分的s1p受体调节剂
WO2008099781A1 (ja) * 2007-02-13 2008-08-21 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤
TW200946105A (en) * 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
JPWO2009142194A1 (ja) * 2008-05-19 2011-09-29 杏林製薬株式会社 光学活性アミノアルコール誘導体の製造方法
JP2010013407A (ja) * 2008-07-04 2010-01-21 Kyorin Pharmaceut Co Ltd アミノアルコール誘導体
JP2010077053A (ja) * 2008-09-25 2010-04-08 Kyorin Pharmaceut Co Ltd フェノール誘導体及びそれらを有効成分とする医薬
HRP20141065T1 (hr) * 2009-07-09 2015-02-13 Kyorin Pharmaceutical Co., Ltd. Derivati difenil-sulfida i lijekovi koji ih sadrže kao aktivni sastojak
JP2011032226A (ja) * 2009-08-03 2011-02-17 Kyorin Pharmaceutical Co Ltd ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6963012B2 (en) * 2001-09-27 2005-11-08 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
CN100351244C (zh) * 2002-05-27 2007-11-28 诺瓦提斯公司 双芳族链烷醇
WO2005014525A2 (en) * 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Bi-aryl compound having immunosuppressive activity
WO2005044780A1 (ja) * 2003-11-10 2005-05-19 Kyorin Pharmaceutical Co., Ltd. アミノカルボン酸誘導体とその付加塩及びｓ１ｐ受容体調節剤
WO2006041015A1 (ja) * 2004-10-12 2006-04-20 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体とその付加塩及び免疫抑制剤
JP2007001921A (ja) * 2005-06-23 2007-01-11 Kyorin Pharmaceut Co Ltd アミノスルホン酸誘導体とその付加塩及びｓ１ｐ受容体調節剤
WO2010042998A1 (en) * 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
MASATOSHI KIUCHI, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 8, 1998, pages 101
MASATOSHI KIUCHI, J. MED. CHEM., vol. 43, 2000, pages 2946
RYOJI HIROSE, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 6, 1996, pages 2647
See also references of EP2786982A4 *
TETSURO FUJITA E, J. MED. CHEM., vol. 39, 1996, pages 4451
TETSURO FUJITA, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 5, 1995, pages 1857
TETSURO FUJITA, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 5, 1995, pages 847

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014175287A1 (ja) 2013-04-26 2014-10-30 国立大学法人 京都大学 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物
CN111087359A (zh) * 2018-10-24 2020-05-01 中国医学科学院药物研究所 艾托莫德的制备方法
CN111087358A (zh) * 2018-10-24 2020-05-01 中国医学科学院药物研究所 普赛莫德的制备方法
CN111087358B (zh) * 2018-10-24 2022-06-21 中国医学科学院药物研究所 普赛莫德的制备方法
CN111087359B (zh) * 2018-10-24 2022-06-21 中国医学科学院药物研究所 艾托莫德的制备方法

Also Published As

Publication number Publication date
CN102863345A (zh) 2013-01-09
EP2786982A1 (en) 2014-10-08
CN103702973A (zh) 2014-04-02
EA201490221A1 (ru) 2014-12-30
KR20140048239A (ko) 2014-04-23
JP2014523887A (ja) 2014-09-18
EP2786982A4 (en) 2015-04-15
CN103702973B (zh) 2016-01-20
US20140323501A1 (en) 2014-10-30

Similar Documents

Publication Publication Date Title
WO2013004190A1 (zh) 胺基丙二醇类衍生物、其制备方法和其药物组合物与用途
KR20040017227A (ko) 엔-아릴페닐아세트아미드 유도체 및 이를 함유하는약제학적 조성물
JP2014523887A5 (enExample)
JPH07505407A (ja) インドール誘導体
WO2004082621A2 (en) Novel ppar agonists, pharmaceutical compositions and uses thereof
CN111662294A (zh) 一类具有降解Btk活性的化合物
CN107163012A (zh) 一类3‑烃基‑5,6‑二氧取代苯酞化合物及其制备方法和用途
CN104844533B (zh) 含五元芳杂环的氨基丙二醇类化合物、其制备方法及其医药用途
CN112076180B (zh) 抗高血压的多元醇化合物及其衍生物
TW200521126A (en) Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders
FI105270B (fi) Menetelmä terapeuttisesti käyttökelpoisten oktahydro-1H-1-pyrindiini-4,5,6,7-terolien valmistamiseksi
WO2019091046A1 (zh) 一种来那度胺的衍生物的制备方法与应用
CN103097363A (zh) 羟基丙二醇类衍生物、其制备方法和其药物组合物与用途
CN102516066B (zh) Ostopanic acid类似物及制备方法及用途
CN101768130B (zh) 含氨甲基五元芳香杂环4-羧酸类衍生物、其制备方法和用途
CN101386580A (zh) 氨基丙二醇类衍生物、其制备方法和其药物组合物与用途
CN107056819B (zh) 一种预防和治疗心肌缺血的药物及其制备方法
CN113105313A (zh) 苯酚衍生物及其医药用途
CN115583890B (zh) 一种治疗血脂异常的药物及其用途
JP4745491B2 (ja) インドール長鎖アルコール及びこれを含有する医薬
KR20000075907A (ko) (ｅ)-4,6-디클로로-3-(2-옥소-1-페닐피롤리딘-3-일리덴 메틸)-1ｈ-인돌-2-카르복실산의 결정질 수화 나트륨염
CN112552276B (zh) 苯并氧杂卓-5-酮类化合物及其制备方法和用途
CN107663202B (zh) 3-(脲基-甲基)-4-芳基-吡啶衍生物及其制备方法和作为抗肝癌药物的应用
CN121135649A (zh) 一类双螺环化合物的制备和医药用途
CN105878243B (zh) 吡非尼酮衍生物在制药中的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12808109

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2014517431

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012808109

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20147003101

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201490221

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 14130861

Country of ref document: US